Clinical commentary on ‘Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis’,by Foley et al.

Abstract

This clinical commentary discusses the occurrence of drug-induced aseptic meningitis in patients undergoing natalizumab treatment and other immunotherapies.

Keywords

Natalizumab disease-modifying therapies adverse drug reaction drug-induced aseptic meningitis

Get full access to this article

View all access options for this article.

References

Foley

Tagg

Schindler

et al . Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis. Mult Scler 2017; 23: 1424–1427.

Moris

Garcia-Monco

JC.

The challenge of drug-induced aseptic meningitis revisited. JAMA Int Med 2014; 174: 1511–1512.

Bharat

Eckert

Kang

et al . Incidence and natural history of intravenous immunoglobulin–induced aseptic meningitis: A retrospective review at a single tertiary care center. Transfusion 2015; 55: 2597–2605.

Mishra

Singh

Pritchard

CH.

Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis. Rheumatol Int 2011; 31: 481–484.

Rothhammer

Muschaweckh

Gasteiger

et al . α4-integrins control viral meningoencephalitis through differential recruitment of T helper cell subsets. Acta Neuropathol Commun 2014; 2: 27 2.

Cherin

Marie

Michallet

et al . Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence. Autoimmunity Rev 2016; 15: 71–81.